157 related articles for article (PubMed ID: 28197106)
1. Inhibition of Intermediate-Conductance Calcium-Activated K Channel (KCa3.1) and Fibroblast Mitogenesis by α-Linolenic Acid and Alterations of Channel Expression in the Lysosomal Storage Disorders, Fabry Disease, and Niemann Pick C.
Oliván-Viguera A; Lozano-Gerona J; López de Frutos L; Cebolla JJ; Irún P; Abarca-Lachen E; García-Malinis AJ; García-Otín ÁL; Gilaberte Y; Giraldo P; Köhler R
Front Physiol; 2017; 8():39. PubMed ID: 28197106
[TBL] [Abstract][Full Text] [Related]
2. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
Oliván-Viguera A; Valero MS; Murillo MD; Wulff H; García-Otín AL; Arbonés-Mainar JM; Köhler R
PLoS One; 2013; 8(3):e58614. PubMed ID: 23516517
[TBL] [Abstract][Full Text] [Related]
3. Lyso-globotriaosylceramide downregulates KCa3.1 channel expression to inhibit collagen synthesis in fibroblasts.
Choi JY; Shin MY; Suh SH; Park S
Biochem Biophys Res Commun; 2015 Dec; 468(4):883-8. PubMed ID: 26592662
[TBL] [Abstract][Full Text] [Related]
4. Calcium-dependent potassium channels control proliferation of cardiac progenitor cells and bone marrow-derived mesenchymal stem cells.
Vigneault P; Naud P; Qi X; Xiao J; Villeneuve L; Davis DR; Nattel S
J Physiol; 2018 Jun; 596(12):2359-2379. PubMed ID: 29574723
[TBL] [Abstract][Full Text] [Related]
5. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.
Coleman N; Brown BM; Oliván-Viguera A; Singh V; Olmstead MM; Valero MS; Köhler R; Wulff H
Mol Pharmacol; 2014 Sep; 86(3):342-57. PubMed ID: 24958817
[TBL] [Abstract][Full Text] [Related]
6. Globotriaosylceramide-induced reduction of K
Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N
Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of KCa3.1 by depolarisation and 2-aminoethoxydiphenyl borate (2-APB) during Ca²⁺ release activated Ca²⁺ (CRAC) entry in human erythroleukemia (HEL) cells: Implications for the interpretation of 2-APB inhibition of CRAC entry.
Littlechild R; Zaidman N; Khodaverdi D; Mason MJ
Cell Calcium; 2015 Feb; 57(2):76-88. PubMed ID: 25601026
[TBL] [Abstract][Full Text] [Related]
8. The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis.
Xie H; Lu J; Zhu Y; Meng X; Wang R
Toxicol Lett; 2018 Oct; 295():408-415. PubMed ID: 30036685
[TBL] [Abstract][Full Text] [Related]
9. Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-
Brown BM; Shim H; Zhang M; Yarov-Yarovoy V; Wulff H
Mol Pharmacol; 2017 Oct; 92(4):469-480. PubMed ID: 28760780
[TBL] [Abstract][Full Text] [Related]
10. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.
Oliván-Viguera A; Valero MS; Coleman N; Brown BM; Laría C; Murillo MD; Gálvez JA; Díaz-de-Villegas MD; Wulff H; Badorrey R; Köhler R
Mol Pharmacol; 2015 Feb; 87(2):338-48. PubMed ID: 25468883
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).
Christophersen P; Wulff H
Channels (Austin); 2015; 9(6):336-43. PubMed ID: 26217968
[TBL] [Abstract][Full Text] [Related]
12. Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.
Jenkins DP; Yu W; Brown BM; Løjkner LD; Wulff H
Assay Drug Dev Technol; 2013; 11(9-10):551-60. PubMed ID: 24351043
[TBL] [Abstract][Full Text] [Related]
13. Structure, Gating and Basic Functions of the Ca2+-activated K Channel of Intermediate Conductance.
Sforna L; Megaro A; Pessia M; Franciolini F; Catacuzzeno L
Curr Neuropharmacol; 2018; 16(5):608-617. PubMed ID: 28875832
[TBL] [Abstract][Full Text] [Related]
14. K
Bonito B; Sauter DR; Schwab A; Djamgoz MB; Novak I
Pflugers Arch; 2016 Nov; 468(11-12):1865-1875. PubMed ID: 27752766
[TBL] [Abstract][Full Text] [Related]
15. Elevated interleukin-8 expression by skin fibroblasts as a potential contributor to pain in women with Fabry disease.
Hofmann L; Grüner J; Klug K; Breyer M; Klein T; Hochheimer V; Wagenhäuser L; Wischmeyer E; Üçeyler N
PLoS One; 2024; 19(4):e0300687. PubMed ID: 38593151
[TBL] [Abstract][Full Text] [Related]
16. Calcium-gated K
Tarasov MV; Bystrova MF; Kotova PD; Rogachevskaja OA; Sysoeva VY; Kolesnikov SS
Pflugers Arch; 2017 Feb; 469(2):349-362. PubMed ID: 28028617
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of
Kloza M; Baranowska-Kuczko M; Toczek M; Kusaczuk M; Sadowska O; Kasacka I; Kozłowska H
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450834
[TBL] [Abstract][Full Text] [Related]
18. New Insights on KCa3.1 Channel Modulation.
Manfroni G; Ragonese F; Monarca L; Astolfi A; Mancinelli L; Iannitti RG; Bastioli F; Barreca ML; Cecchetti V; Fioretti B
Curr Pharm Des; 2020; 26(18):2096-2101. PubMed ID: 32175839
[TBL] [Abstract][Full Text] [Related]
19. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
20. Gal-3 (Galectin-3) and K
She G; Hou MC; Zhang Y; Zhang Y; Wang Y; Wang HF; Lai BC; Zhao WB; Du XJ; Deng XL
Hypertension; 2020 Feb; 75(2):393-404. PubMed ID: 31838908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
